Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fingolimod

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    59 result(s) found for: Fingolimod. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2022-004331-23 Sponsor Protocol Number: FNO-RS1-TERIFIN Start Date*: 2023-03-23
    Sponsor Name:Fakultní nemocnice Ostrava
    Full Title: The importance of therapeutic monitoring of teriflunomide and fingolimod in the treatment of multiple sclerosis
    Medical condition: multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10064137 Progression of multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005677-23 Sponsor Protocol Number: CFTY720D2311 Start Date*: 2013-04-02
    Sponsor Name:Novartis Farma
    Full Title: A two-year, double-blind, randomized, multicenter, active controlled study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ...
    Medical condition: Relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) LT (Completed) SK (Trial now transitioned) LV (Ongoing) ES (Ongoing) DE (Trial now transitioned) BG (Completed) PL (Completed) AT (Completed) NL (Completed) SE (Ongoing) GB (GB - no longer in EU/EEA) RO (Trial now transitioned) EE (Completed) FR (Trial now transitioned) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001012-19 Sponsor Protocol Number: CFTY720DNL02T Start Date*: 2014-12-17
    Sponsor Name:VU University Medical Center
    Full Title: Effects of fingolimod on functional brain adaptation and clinical measures in multiple sclerosis
    Medical condition: Relapsing-remitting (RR) multiple sclerosis (MS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001241-24 Sponsor Protocol Number: CFTY720D2409 Start Date*: 2014-07-30
    Sponsor Name:Novartis Pharma Service AG
    Full Title: Long-term, open-label, multicenter study assessing long-term cardiovascular risks in patients treated with fingolimod
    Medical condition: Cardiovascular risk
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005507-40 Sponsor Protocol Number: CFTY720DIT07 Start Date*: 2013-04-15
    Sponsor Name:NOVARTIS FARMA S.p.A
    Full Title: An open-label, single arm study to provide access to fingolimod to MS patients who completed fingolimod phase IIIb studies and who benefited from treatment with fingolimod or do not have suitable a...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000674-31 Sponsor Protocol Number: CFTY720DDE15TS Start Date*: 2012-08-01
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 3-year, multi-center study to describe the long term changes of optical coherence tomography (OCT) parameters in patients under treatment with Gilenya®
    Medical condition: RNFLT in Patients with relapsing remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004128-41 Sponsor Protocol Number: WN42086 Start Date*: 2021-08-24
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICACY OF OCRELIZUMAB IN COMPARISON WITH FINGOLIMOD IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTI...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) BG (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003484-30 Sponsor Protocol Number: CFTY720DES03 Start Date*: 2011-10-26
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A multi-centre, open-label, non-randomised, parallel group clinical trial to assess the efficacy of fingolimod in naïve patients versus fingolimod in patients previously treated with interferons or...
    Medical condition: Multiple Sclerosis relapsing-remitting course
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-020515-37 Sponsor Protocol Number: CFTY720D2399 Start Date*: 2010-08-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A single arm, open-label, multicenter study evaluating the long-term, safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multip...
    Medical condition: multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) PT (Completed) CZ (Completed) ES (Completed) SK (Completed) HU (Completed) GB (Completed) SE (Completed) FR (Completed) EE (Completed) IT (Completed) AT (Completed) GR (Completed) NL (Completed) IE (Completed) BE (Completed) DK (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2012-000411-91 Sponsor Protocol Number: NKZellen-Version1.0 Start Date*: 2013-02-13
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial
    Medical condition: relapsing-remitting multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002637-11 Sponsor Protocol Number: CFTY720DDE19 Start Date*: 2012-10-15
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 6 months, randomized, multicenter, parallel-group, open-label study to evaluate the effect of an individualized patient support program on treatment satisfaction in Fingolimod (FTY720)-treated pa...
    Medical condition: Treatment statisfaction in patients with relapsing remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024017-31 Sponsor Protocol Number: CFTY720DIT02 Start Date*: 2011-03-15
    Sponsor Name:NOVARTIS FARMA
    Full Title: A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting...
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000835-18 Sponsor Protocol Number: CFTY720D2306E1 Start Date*: 2012-11-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Open-label, single-arm extension study to the double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally ...
    Medical condition: Primary progressive multiple sclerosis.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) BE (Completed) ES (Prematurely Ended) IT (Completed) NL (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) FR (Completed) DK (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002700-39 Sponsor Protocol Number: CBAF312D2301 Start Date*: 2021-09-10
    Sponsor Name:Novartis Pharma AG
    Full Title: A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followe...
    Medical condition: Multiple Sclerosis in pediatric patients
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PT (Trial now transitioned) EE (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) LT (Prematurely Ended) AT (Trial now transitioned) SK (Trial now transitioned) ES (Ongoing) LV (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) HR (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000704-17 Sponsor Protocol Number: CFTY720D2302 Start Date*: 2006-10-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ...
    Medical condition: Relapsing-remitting multiple sclerosis (RRMS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) BE (Completed) AT (Completed) HU (Completed) PT (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004616-21 Sponsor Protocol Number: CFTY720D2415T Start Date*: 2014-03-13
    Sponsor Name:Universitätsklinikum Münster
    Full Title: A 32-week, monocentric, exploratory, single arm study to assess immune function and MRI disease activity in patients with relapsing remitting multiple sclerosis (RRMS) transferred from previous tre...
    Medical condition: relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002968-27 Sponsor Protocol Number: CFTY720D2402 Start Date*: 2013-01-29
    Sponsor Name:Novartis Farmaceutica, S.A
    Full Title: A 48-week, double-blind, randomized, multi-center, parallelgroup study comparing structural changes in the retina and evolution of visual function after immediate versus delayed treatment with fing...
    Medical condition: acute demyelinating optic neuritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) GB (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001442-15 Sponsor Protocol Number: CFTY720D2324 Start Date*: 2011-08-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 32-week, patient- and rater-blinded, randomized, multi-center, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from...
    Medical condition: relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) ES (Completed) GR (Prematurely Ended) AT (Prematurely Ended) CZ (Completed) FI (Prematurely Ended) HU (Completed) SE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002694-66 Sponsor Protocol Number: 01062012 Start Date*: 2012-10-12
    Sponsor Name:Sakari Simula
    Full Title: Effect of fingolimod on cardiac autonomic regulation in MS-patients
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002627-32 Sponsor Protocol Number: 2007-002627-32 Start Date*: 2009-02-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5mg fingolimod administered orally once daily versus placebo in patients wit...
    Medical condition: Primary progressive multiple sclerosis.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) FI (Completed) SE (Completed) ES (Completed) FR (Completed) IT (Completed) DE (Completed) NL (Completed) BE (Completed) HU (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 11:49:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA